Frontiers in Endocrinology,
Journal Year:
2022,
Volume and Issue:
13
Published: June 9, 2022
Nonalcoholic
fatty
liver
disease
(NAFLD)
is
the
dominant
cause
of
worldwide.
steatohepatitis
(NASH),
a
more
aggressive
presentation
NAFLD,
characterized
by
severe
hepatocellular
injury,
inflammation,
and
fibrosis.
Chronic
inflammation
heightened
immune
cell
activity
have
emerged
as
hallmark
features
NASH
key
drivers
fibrosis
through
activation
hepatic
stellate
cells
(HSCs).
Recent
advances
in
our
understanding
molecular
cellular
pathways
highlighted
extensive
crosstalk
between
HSCs
populations
that
strongly
influences
activity.
Here,
we
review
these
findings,
emphasizing
roles
immunity
cell-cell
interactions,
exciting
areas
for
future
investigation.
Nature reviews. Immunology,
Journal Year:
2021,
Volume and Issue:
22(7), P. 429 - 443
Published: Nov. 5, 2021
Non-alcoholic
fatty
liver
disease
(NAFLD)
includes
a
range
of
hepatic
manifestations,
starting
with
steatosis
and
potentially
evolving
towards
non-alcoholic
steatohepatitis
(NASH),
cirrhosis
or
even
hepatocellular
carcinoma.
NAFLD
is
major
health
burden,
its
incidence
increasing
worldwide.
Although
it
primarily
disturbed
metabolism,
involves
several
immune
cell-mediated
inflammatory
processes,
particularly
when
reaching
the
stage
NASH,
at
which
point
inflammation
becomes
integral
to
progression
disease.
The
cell
landscape
diverse
steady
state
further
evolves
during
NASH
direct
consequences
for
severity.
In
this
Review,
we
discuss
current
concepts
related
role
cells
in
onset
NASH.
A
better
understanding
mechanisms
by
contribute
pathogenesis
should
aid
design
innovative
drugs
target
therapeutic
options
are
limited.
(NASH)
serious
chronic
disorder
prevalence
Metabolic
nature,
also
mobilizes
system.
Here,
Huby
Gautier
knowledge
regarding
how
subsets
affect
progression.
